# SCIENTIFIC REPORTS

Received: 20 May 2016 Accepted: 07 September 2016 Published: 23 September 2016

## **OPEN** The UPR inducer DPP23 inhibits the metastatic potential of MDA-MB-231 human breast cancer cells by targeting the Akt–IKK– NF-κB-MMP-9 axis

Soon Young Shin<sup>1,2</sup>, Chang Gun Kim<sup>2</sup>, You Jung Jung<sup>2</sup>, Yoongho Lim<sup>3</sup> & Young Han Lee<sup>1,2</sup>

(E)-3-(3,5-dimethoxyphenyl)-1-(2-methoxyphenyl)prop-2-en-1-one (DPP23) is a synthetic polyphenol derivative that selectively induces apoptosis in cancer cells through the unfolded protein response pathway. In the present study, we evaluated the effect of DPP23 on tumour invasion and metastasis. Here, we show that DPP23 inhibited tumour necrosis factor alpha (TNF $\alpha$ )-induced motility, F-actin formation, and the invasive capability of MDA-MB-231 cells. DPP23 inhibited NF-κB-dependent MMP-9 expression at the transcriptional level. Akt is involved in the activation of IKK, an upstream regulator of NF- $\kappa B$ . DPP23 inhibited IKK and Akt, and knockdown of Akt2 significantly inhibited  $TNF\alpha$ -induced IKK phosphorylation. We found that DPP23 bound to the catalytic domain of Akt2, as revealed by an *in silico* molecular docking analysis. These results suggest that DPP23 prevents  $TNF\alpha$ -induced invasion of highly metastatic MDA-MB-231 breast cancer cells by inhibiting Akt-IKK-NF-KB axis-mediated MMP-9 gene expression. In addition, DPP23 attenuated experimental liver metastasis in a syngenic intrasplenic transplantation model using 4T1 mouse mammary carcinoma cells. Collectively, these results suggest that DPP23 could be used as a potential platform for the prevention of invasion and metastasis of early-stage breast cancer or as an adjuvant for chemo/radiotherapy.

Metastasis is a hallmark of malignant cancer<sup>1</sup>, which is characterized by the spread of primary tumour cells to distant parts of the body. Breast cancer is the most common type of female malignant disease worldwide. The highly invasive and metastatic properties of breast cancer are the main cause of death. Thus, the prevention or appropriate blockade of metastasis at early stages is important for the successful treatment of breast cancer.

Flavonoids are polyphenolic compounds that are found in many edible plants, including fruits and vegetables. Based on their chemical structures, they can be classified into several classes, such as chalcones, flavonols, flavones, flavanones, anthocyanidins, and isoflavonoids. Of these classes, chalcones (1,3,-diphenyl-2-propene-1-ones) consist of two aromatic rings, which are joined together by a three-carbon moiety<sup>2</sup>. Many natural or synthesized chalcones have been reported to exhibit pharmacological activities, including antitumor activity<sup>2-8</sup>. DPP23, (E)-3-(3,5-dimethoxyphenyl)-1-(2-methoxyphenyl)prop-2-en-1-one, is a synthetic chalcone derivative (Fig. 1a)9. We previously reported that DPP23 induces reactive oxygen species (ROS) accumulation and triggers apoptosis through the unfolded protein response (UPR) in the endoplasmic reticulum9. This cytotoxic effect of DPP23 has been observed in various cancer cells, including MiaPaCa-2 and Capan-1 pancreatic cancer cells, HCT116 colon cancer cells, HT1080 fibrosarcoma cells, U87MG glioma cells, and MDA-MB-231 breast cancer cells, but not in non-transformed cells. Thus, DPP23 appears to exert a general anti-tumour effect in diverse cancer cell types. However, the protective effects of DPP23 on tumour invasion and metastasis are currently unknown.

<sup>1</sup>Department of Biological Sciences, College of Biological Science and Biotechnology, Konkuk University, Seoul 05029, Republic of Korea. <sup>2</sup>Cancer and Metabolism Institute, Konkuk University, Seoul 05029, Republic of Korea. <sup>3</sup>Division of Bioscience and Biotechnology, College of Biological Science and Biotechnology, BMIC, Konkuk University, Seoul 05029, Republic of Korea. Correspondence and requests for materials should be addressed to Y.L. (email: yoongho@konkuk.ac.kr) or Y.H.L. (email: yhlee58@konkuk.ac.kr)

а



(E)-3-(3,5-dimethoxyphenyl)-1-(2-methoxyphenyl)prop-2-en-1-one (DPP23)





Tumour metastasis is regulated by a complex series of steps, including the disruption of the basement membrane, degradation of the surrounding extracellular matrix (ECM), increase in motility, intravasation, extravasation, and metastatic growth. The basement membrane is a fibrous, dense meshwork structure of ECM that functions to anchor the epithelium to the underlying connective tissues. Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that are capable of degrading ECM proteins and are mainly involved in tissue remodelling. Among them, gelatinases, including MMP-2 and MMP-9, can degrade the major structural components of basement membranes, including type IV collagen<sup>10</sup>. The NF-KB family of transcription factors has an important role in the regulation of the transcription of many genes<sup>11</sup>. The NF-KB family contains five members: ReIA (known as p65), ReIB, c-Rel, NF-KB1, and NF-KB2. In unstimulated cells, NF-KB dimers are bound to the inhibitor of  $\kappa$ B (I $\kappa$ B). Upon stimulation, the I $\kappa$ B kinase complex (IKK) phosphorylates I $\kappa$ B on Ser32, causing the rapid degradation of IKB, leading to the release of NF-KB from IKB, its translocation into the nucleus, and stimulation of its target genes. In many types of cancer, NF-KB is constitutively activated and contributes to cancer progression, including the up-regulation of MMPs<sup>12</sup>. The IKK complex is composed of three subunits (IKK $\alpha$ , IKK $\beta$ , and IKK $\gamma$ ). Akt (protein kinase B) is a Ser/Thr kinase downstream of phosphatidylinositol 3-kinase (PI3K), which functions as a regulator of cell proliferation and apoptosis<sup>13</sup> and is involved in tumourigenesis in many cancer cells<sup>14</sup>. It has been reported that Akt controls NF-KB activation by activating IKK<sup>15-20</sup>.

In this study, we investigated the effects of DPP23 on anti-metastatic activity using the highly metastatic MDA-MB-231 human breast cancer cells and a syngenic experimental liver metastasis model *in vivo*. We found that DPP23 inhibits the TNF $\alpha$ -induced invasion of MDA-MB-231 cells by targeting the Akt-IKK-NF- $\kappa$ B axis to inhibit expression of the MMP-9 gene.



**Figure 2.** Effect of DPP23 on the invasion of MDA-MB-231 cells. (a) Schematic representation of threedimensional spheroid formation and protrusion of MDA-MB-231 cells (*left*). MDA-MB-231 cell spheroids in the ECM were untreated (control) or treated with 10 ng/mL TNF $\alpha$  for 8 days in the presence or absence of 10  $\mu$ M DPP23. The morphology of the invasive protrusions was captured with an EVOS FL Auto Cell Imaging System (*right panels*). The boxed areas are enlarged. (b) The invasive area was quantified using ImageJ software. Error bars represent the mean  $\pm$  SD of three independent experiments. Statistical significant differences were determined by one-way ANOVA followed by Sidak's multiple comparisons test. \*\*P < 0.001 (n = 3).

#### **Results and Discussion**

**DPP23 reduces TNF** $\alpha$ -induced migration of MDA-MB-231 breast cancer cells. Motility is an essential feature of metastatic cancer cells<sup>21</sup>. In the tumour microenvironment, TNF $\alpha$  plays a critical role in the migration and invasion of tumour cells<sup>22</sup>. An *in vitro* scratch wound-healing assay was performed to determine whether DPP23 affects the TNF $\alpha$ -induced migration of MDA-MB-231 cells. The MDA-MB-231 monolayer was scratched with a pipette tip, and the cells were then allowed to migrate in the presence and absence of TNF $\alpha$  and DPP23. As expected, TNF $\alpha$  enhanced the migration of MDA-MB-231 cells into the scratched area compared with the migration of the untreated cells (Fig. 1b). However, TNF $\alpha$ -induced cell migration was significantly reduced in the presence of DPP23 (P < 0.0001 by one-way ANOVA followed by Sidak's multiple comparisons test, n = 3; Fig. 1c). The actin cytoskeleton plays a key role in cell motility<sup>23</sup>. During cell movement, globular actin monomers (G-actin) are organized into filamentous bundles (F-actin). To determine whether DPP23 alters actin reorganization, the cells were treated with TNF $\alpha$  in the presence of DPP23. Polymerized F-actin was stained with rhodamine-labelled phalloidin, which selectively binds to F-actin. The cells treated with DPP23 exhibited a substantial reduction in TNF $\alpha$ -induced F-actin formation, mostly at the cell edges (Fig. 1d).

**DPP23 inhibits TNF** $\alpha$ -induced invasion of MDA-MB-231-derived spheroids. The local invasive capability of tumour cells is considered to be an early step in the complex process of metastasis. A three-dimensional (3-D) spheroid culture system was used to determine the effect of DPP23 on tumour invasion. As shown in Fig. 2a, spheroids of MDA-MB-231 cells were not invasive under unstimulated conditions (Control). When the cells were treated with TNF $\alpha$ , they began to spread out of the spheroid into the surrounding matrix in a characteristic starburst pattern. However, these invasive protrusions were reduced in the presence of DPP23 (Fig. 2a). We calculated the invasive area using ImageJ software and showed that DPP23 significantly inhibited the invasive capability of MDA-MB-231 spheroids (all *P* < 0.0001 by one-way ANOVA followed by Sidak's multiple comparisons test) (Fig. 2b).

**DPP23 downregulates TNF** $\alpha$ -induced MMP-9 mRNA expression. MMPs are proteolytic enzymes that degrade ECM proteins and play an important role in tissue remodelling. The basement membrane is a fibrous ECM that is important for the structural support of epithelial cells and maintains tissue organization. Gelatinases, such as MMP-2 and -9, are members of the MMP family that are able to cleave type IV collagen, a major component of the basement membrane. Gelatinase expression is highly elevated in many malignant human tumours and is strongly correlated with cancer cell invasion and metastasis<sup>24</sup>. To examine whether DPP23 affects MMP-2 or -9 activity, we performed an in-gel gelatinase activity assay. Gelatin zymography showed that the gelatinase activity of MMP-9 was strongly increased upon TNF $\alpha$  stimulation, which was significantly suppressed in the presence of DPP23 (all P < 0.0001 by one-way ANOVA followed by Sidak's multiple comparisons test, n = 3; Fig. 3a).



Figure 3. Inhibitory effect of DPP23 on  $TNF\alpha$ -induced MMP-9 expression. (a) Serum-starved MDA-MB-231 cells were treated with 10 ng/mL of TNF $\alpha$  for 24h in the presence or absence of DPP23 (10 or  $20 \mu$ M). Conditioned media were collected, and gelatinolytic activity was measured using a 10% Zymogram gel (10% Tris-glycine/0.1% gelatin). Zymography band intensities were measured by ImageJ software and expressed as arbitrary units; background intensity level was set to "1". The data are plotted as the mean  $\pm$  SD. P values were determined by one-way ANOVA followed by Sidak's multiple comparisons test (n = 3). (b) MDA-MB-231 cells were untreated or treated with 10 ng/mL TNF $\alpha$  in the presence or absence of 10  $\mu$ M DPP23 for 18 h. Total RNA was isolated, and RT-PCR was then performed. The GAPDH mRNA was used as an internal control. (c) MDA-MB-231 cells were treated as in (b), and the MMP-9 mRNA levels were measured by quantitative real-time PCR. The relative fold changes were normalized to the level of the GAPDH mRNA in the same sample. The data represent the mean  $\pm$  SD of three independent experiments. \*\*P<0.0001 by one-way ANOVA followed by Sidak's multiple comparisons test (n = 3). ns, not significant versus vehicle control. (d) MDA-MB-231 cells were transfected with  $0.2 \mu g$  of pMMP9-Luc(-925/+13) and 50 ng of pRL-null. After 48 h, the cells were treated with 10 ng/mL TNF $\alpha$  in the presence or absence of 10µM DPP23 for 8h, and the luciferase activities were then determined. Firefly luciferase activity was normalized to *Renilla* luciferase activity. The data represent the mean  $\pm$  SD of three independent experiments. \*\*P < 0.0001 by one-way ANOVA followed by Sidak's multiple comparisons test (n = 3). ns, not significant versus vehicle control.

••••••••••

In contrast, no effect on MMP-2 gelatinase activity was observed following TNF $\alpha$  or DPP23 treatment. TNF $\alpha$  upregulates the expression of the MMP-9 gene in many cancer cells<sup>25–28</sup>. We next investigated whether DPP23 alters TNF $\alpha$ -induced expression of the MMP-9 gene. MDA-MB-231 cells were treated with DPP23 prior to stimulation with TNF $\alpha$ . The reverse transcription-polymerase chain reaction (RT-PCR) analysis showed that DPP23 alone had no effect, but substantially reduced TNF $\alpha$ -induced MMP-9 mRNA expression (Fig. 3b). Real-time PCR analysis was performed to precisely quantify the effect of DPP23 on MMP-9 mRNA expression. As shown in Fig. 3c, the MMP-9 mRNA level was increased by 22.4 ± 2.50-fold in response to TNF $\alpha$  stimulation; however, in the presence of DPP23, the level of this mRNA was significantly decreased to 2.27 ± 0.473-fold compared with the vehicle control (*P* < 0.0001 by one-way ANOVA followed by Sidak's multiple comparisons test). To understand the possible mechanism by which DPP23 reduces MMP-9 expression, MDA-MB-231 cells were transfected with an MMP-9 promoter reporter, pMMP9-Luc(-925/+13), and the effect of DPP23 on MMP-9 promoter activity was analysed. As shown in Fig. 3d, DPP23 significantly reduced TNF $\alpha$ -induced MMP-9 promoter activity (*P* < 0.0001 by one-way ANOVA followed by Sidak's multiple comparisons test). These results indicate that DPP23 has the ability to inhibit TNF $\alpha$ -induced MMP-9 expression at the transcriptional level.



Figure 4. Inhibitory effect of DPP23 on TNF $\alpha$ -induced NF- $\kappa$ B activity. (a) MDA-MB-231 cells were transfected with  $0.2 \mu g$  of pMMP9-Luc(-925/+13) and pMMP9-Luc(-925/+13)mtNF $\kappa$ B, along with 50 ng mith of pRL-null. After 48 h, the cells were treated with 10 ng/mL TNF $\alpha$  for 8 h, and the luciferase activities were then determined. Firefly luciferase activity was normalized to Renilla luciferase activity. The data represent the mean  $\pm$  SD of three independent experiments performed in triplicate. \*\*P < 0.0001 by one-way ANOVA followed by Sidak's multiple comparisons test (n = 9). (b) Serum-starved MDA-MB-231 cells were pretreated with DPP23 (10, 15, or  $20 \mu$ M) for 30 min before stimulation with 10 ng/mL TNF $\alpha$ . After 20 min, whole-cell lysates were prepared and immunoblotting was performed using phospho-specific antibodies against I $\kappa B\alpha$ (Ser32), p65 (Ser536), or p65 (Ser468). GAPDH was used as an internal control. (c) MDA-MB-231 cells were transfected with the  $5 \times NF\kappa$ B-Luc plasmid, along with 50 ng of pRL-null. At 48 h post-transfection, the cells were untreated or treated with 10 ng/mL TNF $\alpha$  in the presence or absence of DPP23 (10 or 20  $\mu$ M). The data represent the mean  $\pm$  SD of three independent experiments performed in triplicate. \*\*P < 0.0001 by one-way ANOVA followed by Sidak's multiple comparisons test (n = 9). (d) MDA-MB-231 cells were pretreated with  $15 \mu$ M DPP23 for 30 min before stimulation with 10 ng/mL TNF $\alpha$ . After 20 min, the cells were fixed and incubated with antibodies against  $\alpha$ -tubulin or phospho-p65 (Ser536) for 2 h, followed by incubation with Alexa Fluor 488-conjugated (green signal) or Alexa Fluor 555-conjugated (red signal) secondary antibodies for 30 min. Nuclear DNA was stained with 1 µg/mL Hoechst 33258 for 10 min (blue signal).

**DPP23 suppresses TNF**α-induced NF-κB activation. The MMP-9 gene is regulated by various transcription factors, including AP-1, NF-κB, SP1, Egr-1, and Ets-1<sup>27,29-31</sup>. Of these transcription factors, NF-κB is activated by TNF $\alpha^{31-32}$ . Mutation of the NF-κB binding site within the MMP-9 gene promoter resulted in the suppression of TNF $\alpha$ -induced MMP-9 promoter activity (Fig. 4a), while transfection with empty vector did not affect TNF $\alpha$ -induced reporter activity. These data suggest that NF-κB plays a critical role in TNF $\alpha$ -induced MMP-9 gene transcription. To assess the possibility that the DPP23-induced suppression of MMP-9 promoter activity is associated with the inhibition of NF-κB, MDA-MB-231 cells were pretreated with DPP23 prior to the addition of TNF $\alpha$ , followed by the analysis of NF-κB phosphorylation. The immunoblot analysis showed that DPP23 dose-dependently reduced TNF $\alpha$ -induced phosphorylation of I $\kappa$ B on Ser32 and p65 NF- $\kappa$ B on both Ser536 and Ser438 (Fig. 4b), suggesting that DPP23 targets the I $\kappa$ B upstream kinase. We next tested whether the DPP23-induced inhibition of NF- $\kappa$ B phosphorylation is functionally linked to the inhibition of its transcriptional activity. MDA-MB-231 cells were transfected with an NF- $\kappa$ B *cis*-acting luciferase reporter containing five repeats of NF- $\kappa$ B binding sites (5 × NF $\kappa$ B-Luc). In this reporter system, luciferase activity represents NF- $\kappa$ B-mediated transcriptional activity. TNF $\alpha$  increased luciferase reporter activity 7.4±0.76-fold (Fig. 4c). However, this activity was significantly reduced in the presence of DPP23 compared with the activity in the TNF $\alpha$ -treated group а





(P < 0.0001 by one-way ANOVA followed by Sidak's multiple comparisons test, n = 9). To further determine the effect of DPP23 on the inhibition of NF-κB, p65 phosphorylation on Ser536 was analysed using immunofluorescence microscopy. Upon TNF $\alpha$  stimulation, fluorescent staining for phospho-p65 NF- $\kappa$ B at Ser536 was remarkably increased in the nucleus. However, when the cells were pretreated with DPP23, this phosphorylation was substantially suppressed (Fig. 4d), supporting the assumption that DPP23 inhibits MMP-9 expression by inhibiting the NF-κB-mediated pathway.

DPP23 binds to the catalytic domain of Akt2 in silico. The phosphatidylinositol 3-kinase (PI3K)-Akt signalling pathway can activate NF-κB by phosphorylating IKK<sup>15-19</sup>. Three Akt isoforms (Akt1, Akt2, and Akt3) are expressed in MDA-MB-231 cells<sup>33</sup>. As Akt2 is the predominant form amplified in breast cancer cells<sup>34</sup> and is involved in the invasion and metastasis of breast cancer cells<sup>35</sup>, it is tempting to speculate that DPP23 inhibits NFkB by targeting Akt2. To test this possibility, we determined whether DPP23 could bind to Akt2 using in silico molecular docking simulations. A pan-Akt inhibitor, GSK690693, was used as a reference ligand<sup>36</sup>. The LigPlot analysis showed that twenty-two residues of Akt2 (Leu158, Gly159, Lys160, Phe163, Val166, Ala179, Lys181, Glu200, Leu204, Phe227, Met229, Glu230, Tyr231, Ala232, Glu236, Glu279, Met282, Thr292, Asp293, Phe294, Phe439, and Phe443) were involved in GSK690693 binding; four residues (Lys160, Glu230, Ala232, and Asp293) formed five hydrogen bonds (H-bonds), and eighteen residues formed hydrophobic interactions (Fig. 5a, left panel). Similarly, ten residues (Lys160, Phe163, Val166, Lys181, Thr213, Met229, Glu279, Met282, Thr292, and Asp293) were located in close proximity to the DPP23 binding site (Fig. 5a, right panel). All of these residues except Thr213 were observed in both complexes, two residues (Lys181 and Asp293) formed two H-bonds, and ten residues formed hydrophobic interactions. PyMOL showed that five H-bonds were formed between Akt2 and GSK690693 (Fig. 5b, left panel), while two H-bonds were formed in the Akt2 and DPP23 complex (Fig. 5b, right panel). Based on these data, we suggest that DPP23 may bind to the catalytic domain of Akt2.

**DPP23** inhibits **TNF** $\alpha$ -induced Akt activation. We next examined whether DPP23 inhibits Akt activity. For maximal activation, threonine phosphorylation in the catalytic domain (at Thr308 in Akt1 and Thr309 in Akt2, located in the activation loop) and serine phosphorylation (at Ser473 in Akt1 and Ser474 in the C-terminal hydrophobic motif of Akt) are required  $3^7$ . Figure 6a shows that TNF $\alpha$  increased the phosphorylation of Akt on Ser473/474 and of IKK $\alpha/\beta$  on Ser176/180 in serum-starved MDA-MB-231 cells, while treatment with DPP23 alone had no effect on their basal phosphorylation. However, when cells were pretreated with DPP23, TNF $\alpha$ -induced phosphorylation of Akt1/2 and IKK $\alpha/\beta$  was significantly reduced (all P < 0.0001 by one-way ANOVA followed by Sidak's multiple comparisons test, n = 3). Although Akt1 is important for tumour development, Akt2 is known to play a pivotal role in tumour invasion and metastasis<sup>38-39</sup>. To further investigate the possibility that inhibition of IKK phosphorylation in response to DPP23 treatment is due to the inhibition of Akt, we established MDA-MB-231 variant cell lines that stably expressed an Akt2 shRNA (MB231/shAkt2) or scrambled shRNA (MB231/shCT). Stable knockdown of Akt2 by shRNA was evaluated by immunoblotting (Fig. 6b). Silencing of endogenous Akt2 significantly attenuated the ability of TNF $\alpha$  to induce IKK $\alpha/\beta$  phosphorylation (all P < 0.05 by one-way ANOVA followed by Sidak's multiple comparisons test, n = 3). These findings suggest that DPP23 inhibits IKK activity by targeting Akt, resulting in the suppression of  $TNF\alpha$ -induced NF- $\kappa B$ phosphorylation.

**Akt2 is involved in TNF** $\alpha$ -induced MMP-9 transcription. RT-PCR analysis was performed on MB231/ shCT and MB231/shAkt2 cells to further determine whether the suppression of TNF $\alpha$ -induced MMP-9 expression by DPP23 is functionally linked to the inhibition of Akt2. As shown in Fig. 6c, the induction of MMP-9 mRNA expression by TNF $\alpha$  was substantially reduced in MB231/shAkt2 cells compared with MB231/shCT cells. Real-time PCR analysis demonstrated a 17.07  $\pm$  1.96-fold increase in the level of the MMP-9 mRNA in the MB231/shCT cells, whereas a 6.30  $\pm$  0.56-fold increase was observed in MB231/shAkt2 cells following TNF $\alpha$  stimulation compared with the basal levels (Fig. 6d). These data suggest that Akt plays an important role in the TNF $\alpha$ -induced regulation of MMP-9 transcription in MDA-MB-231 cells. Thus, DPP23 reduces TNF $\alpha$ -induced MMP-9 expression by inhibiting the Akt–IKK–NF+ $\alpha$  axis in MDA-MB-231 cells.

**DPP23 suppresses experimental syngenic liver metastasis** *in vivo*. We next investigated the effect of DPP23 on the anti-metastatic potential of cells using a mouse syngenic intrasplenic metastasis model. We used 4T1 mouse mammary carcinoma cells, which are known to be highly metastatic to the liver<sup>40–41</sup>. On day 1 after the intrasplenic injection of 4T1 cells, the mice were randomly divided into two groups, and phosphate-buffered saline (PBS; n = 4) or 10 mg/kg DPP23 (n = 6) was inoculated in the peritoneum daily for 7 days (Fig. 7a). All mice were euthanized on day 8 after implantation (Fig. 7b). Hematoxylin-Eosin (H&E) staining revealed the marked diffuse expansion of 4T1 cells around the red pulp region of the spleen in both vehicle- and DPP23-treated mice (Fig. 7c). Liver metastasis of 4T1 cells injected to spleen was observed based on markedly increased formation of tumour nodules in the liver of PBS-treated mice (Fig. 7d, bottom panels). In contrast, smaller tumour nodules were observed in the liver of DPP23-treated mice (Fig. 7d, bottom panels). These data suggest that DPP23 has a potent inhibitory effect on the experimental liver metastasis of mouse mammary tumour cells.

In summary, this study shows that DPP23 inhibits the  $TNF\alpha$ -induced invasion of highly metastatic MDA-MB-231 breast cancer cells by targeting the Akt–IKK–NF- $\kappa$ B axis to inhibit the expression of the MMP-9 gene. We also found that DPP23 attenuates experimental liver metastasis in a syngenic intrasplenic transplantation model using 4T1 mouse mammary carcinoma cells. This finding suggests that DPP23 could be used to prevent the invasion and metastasis of early-stage breast cancer or as an adjuvant for chemo/radiotherapy.

#### Methods

**Cells and chemicals.** Human breast carcinoma cells (MDA-MB-231) were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). Mouse mammary carcinoma cells (4T1) were kindly provided by Dr. Jeong-Seok Nam (Gwangju Institute of Science and Technology, Gwangju, ROK). The cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) heat-inactivated foetal bovine serum (Cellgro, Manassas, VA, USA). TNF $\alpha$  was purchased from Sigma-Aldrich (St. Louis, MO, USA). The firefly and *Renilla* Dual-Glo<sup>TM</sup> Luciferase Assay System was purchased from Promega (Madison, WI, USA). The pRL-null plasmid, which encodes *Renilla* luciferase, was also purchased from Promega.

**Cell migration assay.** The migration of MDA-MB-231 cells was determined using an *in vitro* scratch-wound healing assay, as previously described<sup>42</sup>. In brief, a scratch was made on a monolayer of cells with a micropipette tip, and the cells were untreated (control) or treated with 20 ng/mL TNF $\alpha$  in the presence or absence of 10  $\mu$ M DPP23. After 10 h, the cells were photographed with an EVOS<sup>®</sup> FL Auto Cell Imaging System (Life Technologies, Carlsbad, CA, USA). Cell migratory ability was determined by counting the number of cells invading the scratch-wound area. P value was determined by one-way ANOVA followed by Sidak's multiple comparisons test.

**Actin reorganization.** MDA-MB-231 cells grown on glass coverslips were treated with 10 ng/mL TNF $\alpha$  for 12 h in the presence or absence of 10  $\mu$ M DPP23. F-actin was stained using a Rhodamine-Phalloidin-based F-Actin Visualization Biochem Kit<sup>TM</sup> (Cytoskeleton, Inc., Denver, CO), according to the manufacturer's instructions. Fluorescence was analysed with an EVOS<sup>®</sup> FL Auto Cell Imaging System (Life Technologies).

**3-D spheroid culture and invasion assay.** The 3-D invasion assay was performed using the Cultrex 3-D Spheroid Cell Invasion Assay kit (Trevigen, Inc., Gaithersburg, MD, USA), as previously described<sup>7</sup>. Briefly, MDA-MB-231 cell spheroids were formed, embedded in Matrigel-based ECM, and treated with or without 10 ng/mL



С



Figure 6. Inhibitory effect of DPP23 on  $TNF\alpha$ -induced Akt and IKK phosphorylation and MMP-9 mRNA expression. (a) Serum-starved MDA-MB-231 cells were pretreated with or without 10 µM DPP23 for 30 min before stimulation with 10 ng/mL TNFa. After 20 min, whole-cell lysates were prepared and immunoblotting was performed using the phospho-specific antibodies against Akt (Ser473), p65 (Ser536), or p65 (Ser468). GAPDH was used as an internal control. Band intensities were analysed using a quantitative scanning densitometer. The data are plotted as the mean  $\pm$  SD. *P* values were determined by one-way ANOVA followed by Sidak's multiple comparisons test (n = 3). (b) MB231/shCT and MB231/shAkt2 cells were serum-starved for 24 h and then pretreated with  $10\mu$ M DPP23 for 30 min before stimulation with 10 ng/mL TNF $\alpha$ . After 20 min, the cells were lysed and immunoblotting was performed using antibodies against Akt2 and a phospho-specific antibody against IKK $\alpha/\beta$  (Ser176/180). GAPDH was used as an internal control. Band intensities were analysed using a quantitative scanning densitometer. The data are plotted as the mean  $\pm$  SD. *P* values were determined by one-way ANOVA followed by Sidak's multiple comparisons test (n = 3). (c,d) MB231/shCT and MB231/shAkt2 cells were pretreated with 10  $\mu$ M DPP23 for 30 min before stimulation with 10 ng/mL TNF $\alpha$ . After 12 h, the cells were collected and the MMP-9 mRNA levels were measured by RT-PCR (c) and quantitative real-time PCR (d). The data are plotted as the mean  $\pm$  SD. *P* values were determined by one-way ANOVA followed by Sidak's multiple comparisons test. \*\*P < 0.0001 (n = 9).



Figure 7. Inhibitory effect of DPP23 on syngenic liver metastasis *in vivo*. (a) The 4T1 mouse mammary carcinoma cells  $(6 \times 10^4 \text{ cells}/50 \,\mu\text{L})$  were injected into the splenic lobe. After 1 day, the mice were randomly divided into two groups; one group was intraperitoneally administered with PBS (n = 4), while the other group was intraperitoneally administered with PBS (n = 4), while the other group was intraperitoneally administered with PBS (n = 4), while the other group was intraperitoneally administered with PBS (n = 4), while the other group was intraperitoneally administered with PBS (n = 4), while the other group was intraperitoneally administered with PBS (n = 4), while the other group was intraperitoneally administered with PBS (n = 4), while the other group was intraperitoneally administered with PBS (n = 4), while the other group was intraperitoneally administered with PBS (n = 4), while the other group was intraperitoneally administered with PBS (n = 4), while the other group was intraperitoneally administered with PBS (n = 4), while the other group was intraperitoneally administered with PBS (n = 4), while the other group was intraperitoneally administered with PBS (n = 4), while the other group was intraperitoneally administered with PBS (n = 4), while the other group was intraperitoneally administered with PBS (n = 4), while the other group was intraperitoneally administered with PBS (n = 4), while the other group was intraperitoneally administered with PBS (n = 4), while the other group was after implantation of the 4T1 cells, and the spleen and liver tissues were fixed with formalin. (c,d) Images of histologic sections stained with H&E of spleen (c) and liver (d) from mice untreated normal (top panels) or 4T1-implanted mice treated with vehicle (*middle panels*) or DPP23 (*bottom panels*). CV, central vein. Scale bar, 1000  $\mu$ m (left panels) or 400  $\mu$ m (middle panels). \*tumour nodule

 $TNF\alpha$  in the presence or absence of  $10\mu M$  DPP23. Invasive protrusions into the ECM were visualized with an EVOS<sup>®</sup> FL Auto Cell Imaging System (Life Technologies), and the invasive area was quantified using ImageJ software (NIH).

**RT-PCR and quantitative real-time PCR.** Total RNA was extracted using the Isol-RNA lysis reagent (NucleoZOL; Clontech, Mountain View, CA, USA), and PCR was performed as previously described<sup>43</sup>. For quantitative real-time PCR, the TaqMan-iQ<sup>TM</sup> supermix kit (Bio-Rad, Hercules, CA, USA) was used with the Bio-Rad iCycler iQ<sup>TM</sup> thermal cycler, according to the manufacturer's instructions. The TaqMan<sup>TM</sup> fluorogenic probes and gene-specific PCR primers for MMP-9 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) are described elsewhere<sup>43</sup>. The relative fold changes were normalized to the level of the GAPDH mRNA in the same sample.

**In-gel gelatinase assay.** Gelatin zymography was performed using the Novex<sup>®</sup> Zymogram gelatin gel system (Novex, San Diego, CA, USA) according to the manufacturer's instructions. Briefly, serum-starved MDA-MB-231 cells were treated with 10 ng/mL TNF $\alpha$  for 24 h in the presence or absence of DPP23. The conditioned medium was collected and subjected to polyacrylamide gel electrophoresis using 10% Novex<sup>®</sup> pre-cast gels (10% Tris-glycine gel/0.1% gelatin) under nonreducing conditions. After electrophoresis, the proteolytic activity of the MMP enzymes on gelatin was measured as previously reported<sup>31</sup>. Zymography band intensities were expressed as arbitrary units, which set "1" as a background intensity.

**NF-\kappaB-dependent transcriptional activity assay.** MDA-MB-231 cells were transfected with 0.1 µg of the 5 × NF $\kappa$ B-Luc plasmid, which contains five repeats of NF- $\kappa$ B binding sites. At 24 h post-transfection, the cells were treated with 10 ng/mL TNF $\alpha$  in the presence or absence of DPP23 (10 and 20 µM), as previously described<sup>7</sup>. The luciferase activities were measured with a Centro LB960 luminometer (Berthold Technologies; Bad Wildbad, Germany).

**Immunoblot analysis.** The cells were lysed, and the proteins were separated via SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes, and incubated with appropriate primary and secondary

antibodies. Primary antibodies against phospho-IKK $\alpha/\beta$  (Ser176/180), phospho-I $\kappa$ B (Ser32), phospho-p65 (Ser536), and phospho-p65 (Ser468) were obtained from Cell Signaling Technology (Beverly, MA, USA). The glyceraldehyde phosphate dehydrogenase (GAPDH) antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The blots were developed using an enhanced chemiluminescence detection system (GE Healthcare, Piscataway, NJ, USA).

**MMP-9 promoter reporter assay.** The MMP-9 promoter reporters, wild-type pMMP9-Luc(-925/+13), and disrupted NF- $\kappa$ B binding site pMMP9-Luc(-925/+13)mtNF $\kappa$ B are described elsewhere<sup>31</sup>. MDA-MB-231 cells cultured on 12-well plates were transfected with 0.5  $\mu$ g of the MMP-9 promoter reporter constructs, along with 50 ng of the pRL-null plasmid encoding *Renilla* luciferase to monitor transfection efficiency. At 48 h post-transfection, the cells were treated with 10 ng/mL TNF $\alpha$  in the presence or absence of 10  $\mu$ M DPP23. After 8 h, the cells were collected, and the firefly luciferase activities were measured as previously described<sup>31</sup>. Luminescence was measured using a Centro LB960 dual luminometer (Berthold Technologies).

**Immunofluorescence microscopy.** MDA-MB-231 cells plated on coverslips were untreated or treated with 10 ng/mL TNF $\alpha$  in the presence or absence of 10  $\mu$ M DPP23 for 30 min, followed by fixation, permeabilization, and incubation with primary antibodies against  $\alpha$ -tubulin and phospho-p65 (Ser536) for 2 h, as previously described<sup>8</sup>. Secondary antibodies conjugated to Alexa Fluor 488 (Invitrogen; green signal for  $\alpha$ -tubulin) and Alexa Fluor 555 (Invitrogen; red signal for phospho-p65) were incubated with the cells for 30 min, followed by staining of the nuclear DNA (1  $\mu$ g/mL Hoechst 33258 (Sigma-Aldrich), blue signal) for 10 min. The stained cells were examined under an EVOS f1 fluorescence microscope (Advanced Microscopy Group; Bothell, WA, USA).

Molecular docking simulations. Molecular docking experiments were performed on an Intel Core 2 Quad Q6600 (2.4 GHz) Linux PC with Sybyl 7.3 (Tripos, St. Louis, MO), as previously described<sup>44</sup>. 3D0E.pdb was used as the X-ray crystallographic structure of human Akt2<sup>36</sup>. The 3-D structure of DPP23 was determined using X-ray crystallography. All docking experiments were performed on an Intel Core 2 Quad Q6600 (2.4 GHz) Linux PC with Sybyl 7.3 (Tripos). The structure of the apo-protein of Akt2 (apo-3D0E) was prepared using the Sybyl program, and its solution structure was obtained by energy minimization using a previously reported detailed procedure<sup>45</sup>. The root-mean-square deviation between the crystal structure and the apo-protein was 0.1309 Å. The binding sites were determined based on the interpretation of the results analysed by the LigPlot program, as reported in the protein data bank<sup>46</sup>: Ala179, Lys181, Glu200, Met229, Ala232, Glu236, Asp293, and Phe294. A previously reported flexible docking method was used<sup>45</sup>. To confirm whether this docking process was correct, we docked 4-{2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(3S)-piperidin-3-ylmethoxy]-1H-imidazo[4,5-c] pyridin-4-yl}-2-methylbut-3-yn-2-ol (GSK690693) as a reference ligand<sup>36</sup>. The radius for the active site was set to 1.6 Å. The docking process was iterated 30 times, and 30 complexes were generated (Supplementary Fig. S1a). Of them, 23 complexes were bound to the same site of the crystal structure. Their binding energy ranged from -21.94 to -10.42 kcal/mol. Similarly, DPP23 was docked into the apo-3D0E structure (Supplementary Fig. S1b). Thirty complexes bound well, and their binding energy ranged from -9.83 to -8.15 kcal/mol. 3-D images were generated using the PyMOL program (The PyMOL Molecular Graphics System, Version 1.3, Schrödinger, LLC).

**Lentiviral shRNA-mediated gene silencing.** Lentiviral particles expressing a short hairpin RNA (shRNA) targeting Akt2 or a scrambled control were obtained from Sigma-Aldrich (MISSION<sup>®</sup> shRNA; Sigma-Aldrich, St. Louis, MO, USA). MDA-MB-231 cells were transduced with lentiviral particles according to the manufacturer's instructions. Knockdown of Akt2 protein expression was verified by immunoblot analysis.

**Syngenic experimental liver metastasis assay.** Six-week-old female Balb/c mice were purchased from YoungBio (Seongnam, Gyeonggi-do, Republic of Korea). All animal experiments were conducted according to the standards and procedures approved by the Konkuk University Institutional Animal Care and Use Committee (no. KU15194). Balb/c mice were anaesthetized, and the spleen was exposed through a small incision in the left abdominal flank, as previously described<sup>47</sup>. The 4T1 mammary carcinoma cells ( $6 \times 10^4$  cells/ $50 \mu$ L) were injected into the splenic lobe with a 30-gauge needle. The spleen was returned to the abdominal cavity, and the abdominal wall was closed using 6–0 nylon sutures. On day 1 post-implantation of the 4T1 cells, the mice were randomly divided into two groups. One group was intraperitoneally administered with PBS (n = 4), while the other group was intraperitoneally administered with 10 mg/kg DPP23 (n = 6) daily for 7 days. All mice were euthanized on day 8 after implantation, and the spleen and liver tissues were fixed with 10% phosphate buffered formalin and stained with haematoxylin and eosin (H&E).

**Statistical analysis.** The data are presented as the mean  $\pm$  S.D. Statistical analysis was analyzed by one-way analysis of variance (ANOVA) followed by Sidak's multiple comparisons test using GraphPad Prism version 7.0 software (GraphPad Software Inc., La Jolla, CA, USA). *P* values less than 0.05 were considered statistically significant.

#### References

- 1. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
- Orlikova, B., Tasdemir, D., Golais, F., Dicato, M. & Diederich, M. Dietary chalcones with chemopreventive and chemotherapeutic potential. *Genes Nutr* 6, 125–147 (2011).
- Yadav, V. R., Prasad, S., Sung, B. & Aggarwal, B. B. The role of chalcones in suppression of NF-kappaB-mediated inflammation and cancer. Int Immunopharmacol 11, 295–309 (2011).
- Zhang, E. H., Wang, R. F., Guo, S. Z. & Liu, B. An update on antitumor activity of naturally occurring chalcones. Evid Based Complement Alternat Med 2013, 815621 (2013).

- Mahapatra, D. K., Bharti, S. K. & Asati, V. Anti-cancer chalcones: Structural and molecular target perspectives. Eur J Med Chem 98, 69–114 (2015).
- Lee da, H. et al. A synthetic chalcone, 2'-hydroxy-2,3,5'-trimethoxychalcone triggers unfolded protein response-mediated apoptosis in breast cancer cells. Cancer Lett 372, 1–9 (2016).
- Lee, M. S. et al. 2-Hydroxy-3,4-naphthochalcone (2H-NC) inhibits TNFalpha-induced tumor invasion through the downregulation of NF-kappaB-mediated MMP-9 gene expression. *Bioorg Med Chem Lett* 25, 128–132 (2015).
- Shin, S. Y. et al. Novel antimitotic activity of 2-hydroxy-4-methoxy-2''3'-benzochalcone (HymnPro) through the inhibition of tubulin polymerization. J Agric Food Chem 61, 12588–12597 (2013).
- Shin, S. Y. et al. Targeting cancer cells via the reactive oxygen species-mediated unfolded protein response with a novel synthetic polyphenol conjugate. Clin Cancer Res 20, 4302–4313 (2014).
- Terranova, V. P., Hujanen, E. S. & Martin, G. R. Basement membrane and the invasive activity of metastatic tumor cells. J Natl Cancer Inst 77, 311–316 (1986).
- 11. Pahl, H. L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18, 6853–6866 (1999).
- 12. Hoesel, B. & Schmid, J. A. The complexity of NF-kappaB signaling in inflammation and cancer. Mol Cancer 12, 86 (2013).
- 13. Manning, B. D. & Cantley, L. C. AKT/PKB signaling: navigating downstream. Cell 129, 1261–1274 (2007).
- 14. Testa, J. R. & Bellacosa, A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 98, 10983-10985 (2001).
- Sizemore, N., Leung, S. & Stark, G. R. Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit. *Mol Cell Biol* 19, 4798–4805 (1999).
- Li, X. et al. Phosphoinositide 3 kinase mediates Toll-like receptor 4-induced activation of NF-kappa B in endothelial cells. Infect Immun 71, 4414–4420 (2003).
- Giri, S., Rattan, R., Singh, A. K. & Singh, I. The 15-deoxy-delta12,14-prostaglandin J2 inhibits the inflammatory response in primary rat astrocytes via down-regulating multiple steps in phosphatidylinositol 3-kinase-Akt-NF-kappaB-p300 pathway independent of peroxisome proliferator-activated receptor gamma. J Immunol 173, 5196–5208 (2004).
- Nam, K. N., Son, M. S., Park, J. H. & Lee, E. H. Shikonins attenuate microglial inflammatory responses by inhibition of ERK, Akt, and NF-kappaB: neuroprotective implications. *Neuropharmacology* 55, 819–825 (2008).
- Park, H. Y. et al. Anti-inflammatory effects of fucoidan through inhibition of NF-kappaB, MAPK and Akt activation in lipopolysaccharide-induced BV2 microglia cells. Food Chem Toxicol 49, 1745–1752 (2011).
- Dan, H. C. et al. Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev 22, 1490–1500 (2008).
- 21. Zeisberg, M. & Neilson, E. G. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 119, 1429–1437 (2009).
- 22. Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454, 436-444 (2008).
- 23. Fletcher, D. A. & Mullins, R. D. Cell mechanics and the cytoskeleton. Nature 463, 485-492 (2010).
- 24. Egeblad, M. & Werb, Z. New functions for the matrix metalloproteinases in cancer progression. *Nat Rev Cancer* 2, 161–174 (2002).
- 25. Joyce, J. A. & Pollard, J. W. Microenvironmental regulation of metastasis. Nat Rev Cancer 9, 239-252 (2009)
- Lin, C. C. et al. Tumor necrosis factor-[alpha] induces MMP-9 expression via p42/p44 MAPK, JNK, and nuclear factor-[kappa]B in A549 cells. Toxicology and Applied Pharmacology 229, 386–398 (2008).
- Van den Steen, P. E. et al. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Critical reviews in biochemistry and molecular biology 37, 375–536 (2002).
- Rao, V. H. *et al.* Transcriptional regulation of MMP-9 expression in stromal cells of human giant cell tumor of bone by tumor necrosis factor-alpha. *Int.J Oncol.* 14, 291–300 (1999).
- Sato, H. & Seiki, M. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 8, 395–405 (1993).
- Van den Steen, P. E. et al. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 37, 375–536 (2002).
- Shin, S. Y., Kim, J. H., Baker, A., Lim, Y. & Lee, Y. H. Transcription factor Egr-1 is essential for maximal matrix metalloproteinase-9 transcription by tumor necrosis factor alpha. *Mol Cancer Res* 8, 507–519 (2010).
- 32. Balkwill, F. Tumour necrosis factor and cancer. Nat Rev Cancer 9, 361-371 (2009).
- Nakatani, K. et al. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 274, 21528–21532 (1999).
- 34. Toker, A. & Yoeli-Lerner, M. Akt signaling and cancer: surviving but not moving on. Cancer Res 66, 3963–3966 (2006).
- Arboleda, M. J. et al. Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res 63, 196–206 (2003).
- Heerding, D. A. *et al.* Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1Himidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase. *J Med Chem* 51, 5663–5679 (2008).
- Bozulic, L. & Hemmings, B. A. PIKKing on PKB: regulation of PKB activity by phosphorylation. *Curr Opin Cell Biol* 21, 256–261 (2009).
- Dillon, R. L. et al. Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. Cancer Res 69, 5057–5064 (2009).
- Hutchinson, J., Jin, J., Cardiff, R. D., Woodgett, J. R. & Muller, W. J. Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. *Mol Cell Biol* 21, 2203–2212 (2001).
- Pulaski, B. A. & Ostrand-Rosenberg, S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. *Cancer Res* 58, 1486–1493 (1998).
- Aslakson, C. J. & Miller, F. R. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. *Cancer Res* 52, 1399–1405 (1992).
- Shin, S. Y., Nam, J. S., Lim, Y. & Lee, Y. H. TNFalpha-exposed bone marrow-derived mesenchymal stem cells promote locomotion of MDA-MB-231 breast cancer cells through transcriptional activation of CXCR3 ligand chemokines. *J Biol Chem* 285, 30731–30740 (2010).
- 43. Shin, S. Y., Lee, J. M., Lim, Y. & Lee, Y. H. Transcriptional regulation of the growth-regulated oncogene alpha gene by early growth response protein-1 in response to tumor necrosis factor alpha stimulation. *Biochim Biophys Acta* 1829, 1066–1074 (2013).
- 44. Shin, S. Y. *et al.* Chromenylchalcones showing cytotoxicity on human colon cancer cell lines and in silico docking with aurora kinases. *Bioorg Med Chem* **21**, 4250–4258 (2013).
- Shin, S. Y. et al. Polyphenols bearing cinnamaldehyde scaffold showing cell growth inhibitory effects on the cisplatin-resistant A2780/Cis ovarian cancer cells. Bioorg Med Chem 22, 1809–1820 (2014).
- Wallace, A. C., Laskowski, R. A. & Thornton, J. M. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. *Protein Eng* 8, 127–134 (1995).
- Giavazzi, R., Jessup, J. M., Campbell, D. E., Walker, S. M. & Fidler, I. J. Experimental nude mouse model of human colorectal cancer liver metastases. J Natl Cancer Inst 77, 1303–1308 (1986).

### Acknowledgements

This research was supported by Basic Science Research Program through the National Research Foundation of Korea(NRF) funded by the Ministry of Science, ICT and future Planning (grant no. 2015A2A2A01004987). This paper was supported by the KU Research Professor Program of Konkuk University.

#### **Author Contributions**

S.Y.S., Y.L. and Y.H.L. participated in the study design. S.Y.S., C.G.K. and Y.J.J. performed the experiments. Y.L. synthesized the compound and performed the *in silico* docking analysis. S.Y.S., Y.L. and Y.H.L. wrote the main manuscript. All authors reviewed the manuscript. Y.H.L. obtained funding.

### **Additional Information**

Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

**How to cite this article**: Shin, S. Y. *et al.* The UPR inducer DPP23 inhibits the metastatic potential of MDA-MB-231 human breast cancer cells by targeting the Akt–IKK–NF-κB–MMP-9 axis. *Sci. Rep.* **6**, 34134; doi: 10.1038/srep34134 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2016